![David Spellman](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
David Spellman
Nessuna posizione attualmente
Patrimonio netto: - $ in data 31/05/2024
Profilo
David A.
Spellman formerly worked at Vertex Pharmaceuticals, Inc., as VP-Commercial & International Finance, Mersana Therapeutics, Inc., as Chief Financial Officer from 2018 to 2019, Intarcia Therapeutics, Inc., as Chief Financial & Business Officer from 2019 to 2020, and Akebia Therapeutics, Inc., as Treasurer, Chief Financial & Accounting Officer from 2022 to 2023.
Mr. Spellman received his undergraduate degree from The Wharton School of the University of Pennsylvania.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
31/03/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
Precedenti posizioni note di David Spellman
Società | Posizione | Fine |
---|---|---|
AKEBIA THERAPEUTICS, INC. | Direttore Finanziario/CFO | 23/06/2023 |
Intarcia Therapeutics, Inc.
![]() Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Direttore Finanziario/CFO | 29/06/2020 |
MERSANA THERAPEUTICS, INC. | Direttore Finanziario/CFO | 30/06/2019 |
VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | - |
Formazione di David Spellman
The Wharton School of the University of Pennsylvania | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 3 |
---|---|
MERSANA THERAPEUTICS, INC. | Health Technology |
VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
AKEBIA THERAPEUTICS, INC. | Health Technology |
Aziende private | 1 |
---|---|
Intarcia Therapeutics, Inc.
![]() Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
- Borsa valori
- Insiders
- David Spellman